private financing | GenomeWeb

private financing

The Houston- and Slovenia-based data firm wants to boot scientists off Excel spreadsheets and onto its flexible, proprietary platform for data management.

The firm will sell 855,000 shares of its common stock to three investors. It will also sell warrants to the same investors.

The Silicon Valley startup has launched with a proprietary automation platform, and counts CRISPR researcher Jennifer Doudna among its new investors.

The Cambridge, Massachusetts-based precision medicine firm hopes to translate molecular information into therapies for chronic kidney diseases.

The food safety firm is using NGS testing and data analytics to create actionable information for retailers and manufacturers.

The company plans to use the new funding to expand into Asia, with a particular focus on China.

The firm said that the system is unique because it consists of cell, immunoassay, and nucleic acid tests within one platform.   

The firm offered a qualitative assessment of third quarter business activities, and announced a private placement and a US distribution deal with Thermo Fisher.

The firm is building an antibody-based immune system-related protein biomarker test for stroke diagnosis in both community and academic hospitals.

The exome-sequencing consumer genomics startup has added George Church and Dietrich Stephan to its advisory board, along with several others.

Pages

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.